RxDoctor Payments Data

Shannon Sprenkle

Nurse Practitioner · Keyser, WVNPI 1013384072

Payments from drug & device makers

$2,118in general payments, 2019–2025

Across 94 payments — averaging $22.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$866
  • GSK$842
  • Verona Pharma, Inc.$149
  • Baxter Healthcare$71
  • Boehringer Ingelheim$69
  • Amgen$66
  • plus $56 from 1 others

What the payments were for

  • Food & beverage$2,118100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,118 in reported general payments places this provider in the 85th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$12,627
Medicare patients
88
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter414$502,678
OfevNintedanib Esylate13$166,720
Breo ElliptaFluticasone/Vilanterol126$81,327
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$32,186
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr55$30,557
Arnuity ElliptaFluticasone Furoate55$18,190
Incruse ElliptaUmeclidinium Bromide43$17,032
Albuterol Sulfate HfaAlbuterol Sulfate234$11,309
Advair HfaFluticasone Propion/Salmeterol11$7,814
Ventolin HfaAlbuterol Sulfate84$7,759
SymbicortBudesonide/Formoterol Fumarate20$7,712
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$7,086
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$6,123
Roflumilast29$4,152
Advair DiskusFluticasone Propion/Salmeterol11$2,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$842$649,784693 claims
Boehringer IngelheimOfev$69$166,72013 claims
AstraZenecaBreztri Aerosphere, Symbicort$866$39,89860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Keyser

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →